Cian Healthcare (BSE: CHCL) is loss-making over the last 12 months, losing ₹23 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹36.23, 66% below its 52-week high. Sales fell 26% a year over 3 years. Debt is 3.36× equity. It is listed on an SME platform with a market cap of ₹91 Cr, ranked 122nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 67% over the past year.
- ₹36.23
- ₹36.23
- ₹36.23
- ₹35.52
- 274
Health check
- ReturnsBehind
−66.9% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthShrinking
Sales −25.6% a year over 3 years.
- ProfitabilityNegative
ROCE -70.0% vs peer median 17.9%.
- Balance sheetStretched
Debt 3.36× equity, operating profit doesn’t cover interest, Piotroski 4 of 9.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹91 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- 10.61
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- −113.9%
- Peers 14.7%
- ROCE
- −70.0%
- Peers 17.9%
- Debt to equity
- 3.36
- Debt ₹29 Cr
- EPS (TTM)
- −₹9.32
- OPM (TTM)
- −27.6%
- Net margin −82.3%
- Sales growth
- +42.0%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 3.20
- EV/EBITDA −17.8
Strengths and risks
Strengths
- Quarterly sales up 42.0% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −113.9%.
- Debt is 3.36× equity.
- 66% below its 52-week high.
- Interest coverage of only −12.8×.
About Cian Healthcare
Cian Healthcare Limited engages in the research, development, manufacture, marketing, and sale of pharmaceutical products in India. It offers pharmaceutical products in various therapeutic areas of gynecology, cardio- diabetic, orthopedic, pediatric, dermacosmetic, antibiotic, CNS, and vitamins and nutrient products. The company also provides male and female infertility, reproductive wellness, energy boosting, autism, multivitamins, joint care products,…
- Headquarters
- Pune
- Employees
- 170
- Sector
- Healthcare
- ISIN
- INE05BN01027
- Website
- cian.co
Price range
- Avg volume (3M)
- 828
- 1-year return
- minus 66.9%
- From 52-week high
- minus 66.3%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| CHCLCian Healthcare | 36.23 | plus 2.00% | 91 | – | 10.61 | −70.0% | −113.9% | −27.6% | −25.6% | – | 0.00% | minus 66.9% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- Sales CAGR 3Y
- −25.6%
- ROE
- −113.9%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 68.6 | 61.7 | 30.8 | 28.3 | |
| – | minus 10.1% | minus 50.1% | minus 8.1% | |
| 55.5 | 50.4 | 37.3 | 34.6 | |
| 13.1 | 11.3 | −6.5 | −6.3 | |
| 19.1% | 18.3% | −21.2% | −22.1% | |
| 0 | −0.2 | −0.2 | 1.2 | |
| 5.8 | 5.6 | 2.6 | 0.5 | |
| 5.4 | 5.5 | 4.4 | 3.9 | |
| 0.1 | 0 | −12.3 | −13.7 | |
| 2 | 0.1 | −26 | −23.2 | |
| −1.9% | −1528.8% | 0.1% | −0.5% | |
| 2 | 0.8 | −26 | −23.3 | |
| – | minus 58.2% | minus 3161.2% | – | |
| 11.81 | 4.96 | -10.39 | – |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 25 | 25 | 25 | 25 | |
| 32.5 | 33.3 | 7.4 | −16.5 | |
| 60.8 | 55.7 | 55 | 28.7 | |
| 42.2 | 47.1 | 68.7 | 24.4 | |
| 160 | 161 | 156 | 61.6 | |
| 59 | 55.1 | 52 | 38 | |
| 14.4 | 15.8 | 17 | 6.2 | |
| 4.9 | – | – | 0.1 | |
| 1.3 | 1.2 | 17.8 | 1.2 | |
| 80.9 | 89.2 | 69.3 | 16.1 | |
| 160 | 161 | 156 | 61.6 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 4.8 | 11.8 | 20.8 | −1.5 | |
| 2.6 | −1.5 | −0.3 | 13.3 | |
| −7.4 | −10.4 | −3.9 | −28.4 | |
| −0 | −0.1 | 16.6 | −16.6 | |
| −1.3 | −1 | −0.4 | −0.8 | |
| 3.5 | 10.8 | 20.3 | −2.3 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.